Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

A Phase I, Open-labeled Multicenter Study to Determine Pharmacokinetics, Safety, Tolerability and Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.

Study Overview

• Status: Recruiting
• Conditions: Relapsed/Refractory AML
• Intervention / Treatment: Drug: Uproleselan

Detailed Description

This study is a multicenter open-labelled study conducted in subjects with relapsed or refractory AML in China. The study includes the following phases: screening phase, induction phase, consolidation phase baseline, consolidation phase and follow-up period.

Screening phase:

This study will enroll 12 subjects, who are 18 to 60 years (inclusive) at the time of signing the Informed Consent Form (ICF), and with the diagnosis as relapsed or refractory AML. Screening is conducted 21 days to 2 days before administration, and signed ICF by the subject must be obtained before screening.

Baseline period:

The baseline period is 1 day before study drug administration.

Induction treatment:

During the induction phase, subjects will receive 8 consecutive days of uproleselan treatment and 5 consecutive days of MEC (mitoxantrone, etoposide, and cytarabine combined regimen) chemotherapy.

Consolidation baseline:

The baseline of the consolidation phase is 1 day before the treatment administration of the consolidation phase.

Consolidation treatment:

Subjects who met the criteria for consolidation treatment started the consolidation period at the 29th day of the previous treatment cycle at the earliest and the 65th day at the latest.

Follow-up period:

Each subject should complete the following follow-up stage: (1) Response evaluation to determine remission to the induction treatment (induction period); (2) EOT assessment after completing the last consolidation treatment cycle; (3) Death. Survival and long-term follow-up, including initiation of new anti-leukemia treatment (within 6 months after the last uproleselan/placebo administration), recurrence, HSCT and survival events, monthly (±14 days) for 2 years after the end of treatment, and afterwards quarterly (±14 days). The longest survival follow-up time is 3 years (calculated from the start of treatment).

• Study Type: Interventional
• Enrollment (Anticipated): 12
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Hangzhou, China
    • Recruiting
    • The First Affiliated Hospital of Zhejiang University
  • Tianjin
    • Tianjin, Tianjin, China, 300020
      • Recruiting
      • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Key Criteria:

1. ≥18 years and ≤60 years in age
2. AML (including secondary AML) diagnosed as per WHO standards (2008).

3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy.

   1. For relapse AML, it must be the first or second relapse, and remain untreated.
   2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed.
4. ECOG performance status score is 0 to 2.
5. Stable hemodynamics and good organ function and good organ function.

Exclusion key Criteria:

1. Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.
2. Active signs or symptoms of CNS involvement by malignancy.
3. Stem cell transplantation ≤4 months prior to dosing.
4. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.
5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
6. Inadequate organ function.
7. Abnormal liver function.
8. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
9. Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).
10. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
11. Clinically significant cardiovascular disease.
12. Major surgery within 4 weeks of dosing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: A Phase I, open-labeled multicenter study; Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)	Drug: Uproleselan; A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin; Other Names: GMI-1271

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak plasma concentration (Tmax)	To assess the pharmacokinetic profile in patients with relapsed/refractory AML.	14 days
Peak plasma concentration (Cmax)	To assess the pharmacokinetic profile in patients with relapsed/refractory AML.	14 days
Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12)	To assess the pharmacokinetic profile in patients with relapsed/refractory AML.	14 days
The area under the plasma concentration-time curve (AUC0-t) from time zero to the last measurable time point	To assess the pharmacokinetic profile in patients with relapsed/refractory AML.	14 days
The Incidence of Adverse Events	Number of participants with an AE.	Up to 10 months
The tolerance of participants with relapsed/refractory AML.	Number of participants could tolerate the Uproleselan combined with chemotherapy.	Up to 10 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
OS	Defined as the period from when the subject receives the first dose of the study drug to death from any cause;	Up to 3 years
Remission rate (rate of CR, CR/CRi and CR/CRh)	Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh;	Up to 60 days
CTCAE grade 3 and 4 oral mucositis	The incidence of CTCAE grade 3 and 4 oral mucositis during the treatment duration.	Up to 254 days

Collaborators and Investigators

• Sponsor: Apollomics Inc.
• Collaborators: Zhejiang CrownMab Biotech Co. Ltd
• Investigators: Principal Investigator: Jianxiang Wang, Phd, Investigator

Study record dates

Study Major Dates

• Study Start (Actual): February 24, 2021
• Primary Completion (Anticipated): December 31, 2022
• Study Completion (Anticipated): February 28, 2023

Study Registration Dates

• First Submitted: March 22, 2021
• First Submitted That Met QC Criteria: April 7, 2021
• First Posted (Actual): April 9, 2021

Study Record Updates

• Last Update Posted (Actual): September 16, 2021
• Last Update Submitted That Met QC Criteria: September 14, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: AML
• Other Study ID Numbers: APL-106-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No